The changes of intestinal microbiota and metabolomics during the inhibition of bladder cancer by liquiritigenin.

AbstractLiquiritigenin is a natural medicine. However, its inhibitory effect and its potential mechanism on bladder cancer (BCa) remain to be explored. It was found that it could be visualized that the transplanted tumours in the low-dose liquiritigenin -treated group and the high-dose liquiritigenin -treated group were smaller than those in the model group. Liquiritigenin treatment led to alterations in Lachnoclostridium, <italic>Escherichia-Shigella, Alistipes</italic> and <italic>Akkermansia</italic>. Non-targeted metabolomics analysis showed that a total of multiple differential metabolites were identified between the model group and the high-dose liquiritigenin-treated group. This provides a new direction and rationale for the antitumour effects of liquiritigenin. [ABSTRACT FROM AUTHOR]